• Home
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Jacinta Flattery O’Brien PhD
    • Jennifer Enmon PhD JD
    • Grant Shoebridge PhD
    • Kadri Elcoat
    • Kate Legge
    • Lesley White
    • Alex May
    • Christopher Coates
    • Jessica Chadbourne PhD
    • Joanne Grant
    • Emily Bristow
    • Brittany Deleon
    • Erni Othman
    • Amber Cross
  • News
    • Pearce IP Blog
    • BioBlast™
  • Blog
  • BioBlast™
  • Contact Us

Study approves of Sandoz’s Zarxio® as treatment of cancer

by Bioblast Editor | Oct 6, 2020 | Biosimilars updates

Onco’Zine reports a new study released by the American Society of Clinical Oncology Quality Care Symposium indicates that Sandoz’s Zarxio® (biosimilar filgrastim) is not only safe and effective, but is cost effective in treating chemotherapy-induced...

US District Court of Delaware’s rejection of Amgen

by Bioblast Editor | Jul 1, 2020 | Biosimilars updates

The US District Court of Delaware refuses to combine Amgen’s two actions against Pfizer and Hospira relating to filgrastim. The original action was filed in July 2018, and the more recent action was filed in April 2020. In the oral order, (available courtesy of...

Amgen files suit against Hospira and Pfizer

by Bioblast Editor | May 1, 2020 | Biosimilars updates

Amgen filed suit against Hospira and Pfizer, alleging infringement of US patent 10,577,392, relating to the manufacture of Neupogen®. Interestingly, the patent was only granted on March 03, 2020, nearly 2 years after Hospira launched Nivestym®.

New study of Pfizer’s Nivestim® against Neupogen®

by Bioblast Editor | Jan 3, 2020 | Biosimilars updates

New study demonstrates noninferiority of Pfizer’s Nivestim® to reference Neupogen®. Additionally, the study demonstrated that those in the biosimilar group reported a shorter median hospitalisation period by two days.

Amgen and Tanvex’s dismissal in filgrastim dispute

by Bioblast Editor | Dec 19, 2019 | Biosimilars updates

Amgen and Tanvex file a joint stipulation of dismissal in their filgrastim dispute. The stipulation of dismissal states that parties will bear their own costs and attorney’s fees.
Page 1 of 712345...»Last »

SUBSCRIBE TO PEARCE IP

Sign up to our latest news

Receive our Pearce IP Blog and weekly BioBlast™ via email.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast™
  • Contact Us
  • Follow

Copyright © 2021 Pearce IP. All Rights Reserved.

Contact Us

Email: info@pearceIP.law
Tel: +61 (0) 2 9023 9988

For any general inquiries, please fill in the following contact form:

 





    Subscribe to our BioBlast™

    Fill in the form below to recieve our BioBlast™ Updates, Pearce IP Blog and other relevant industry updates.

     



      What emails do you want to receive?